The FDA has accepted Pharming Group’s supplemental new drug application for leniolisib in treating activated phosphoinositide 3-kinase delta syndrome, or APDS, in children aged 4 to 11 years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback